One of the more peculiar ways in which this aging bull market has deviated form historical norms is the sheer number of stocks that have literally doubled or even tripled in value almost overnight — especially in the red-hot biopharmaceutical space. On the flip side, though, a number of these high-flying stocks have been unable to hold on to their monstrous gains due to pipeline setbacks or sizable equity offerings that dilute shareholder value.
Fortunately, there are a handful of names in biopharma that can double your net worth in a far less volatile manner. The only requirement is patience. The large-cap megapharmas AstraZeneca (NYSE:
The tide has finally turned
Over the past four years, AstraZeneca has been battling to regain its footing after the loss of exclusivity for both its acid reflux drug Nexium and cholesterol-lowering medicine Crestor. To do so, the company set its sights on becoming a top player in the high-value oncology space.
While this herculean effort got off to a slower-than-expected start due to its lead checkpoint inhibitor Imfinzi missing the mark in a late-stage study for lung cancer, AstraZeneca has rebounded nicely over the last two years by bringing several other cancer drugs to market and advancing Imfinzi into a slew of other high-dollar indications.
The net result is that AstraZeneca’s oncology portfolio has quietly become one of the best in the business. Right now, for instance, the company sports Lumoxiti for patients with hairy-cell leukemia, Calquence as a treatment for mantle cell lymphoma, Iressa for non-small cell lung cancer, Lynparza for ovarian cancer, and Tagrisso for front line lung cancer. In addition, Imfinzi is finally shaping up into a true flagship product — with…
Continue reading original article at Fool.com